COPD or not COPD, that is the question.
|
|
- Adelia Bailey
- 5 years ago
- Views:
Transcription
1 COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins
2 Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP FDA: PADAC Research Interest - No current industry sponsored clinical trials but have worked with several industries in asthma trials
3 Introduction and Goals Asthma and COPD share many disease features including symptoms, time of onset of disease, and airflow obstruction Features of asthma and COPD may co-exist, especially in older patients, to complicate the recognition of underlying airway diseases and its treatment, particularly in the face of smoking. Discuss Obstructive lung disease classifications Overlap syndrome (ACOS) Approaches to recognition and treatment? Is it a necessary diagnosis
4 Chronic obstructive pulmonary diseases Traditional View Asthma COPD Distinct Diseases
5 Traditional views British hypothesis Dutch hypothesis Spectrum of disease, 1961
6 Obstructive defect A disproportionate reduction of maximal airflow with respect to the maximal lung volume FEV 1 decreases more than FVC FEV 1 /FVC is decreased, should be primary guide
7 Spirometry: Flow-Volume Loops in Demonstrating Non-obstructed Pattern & Reversal of Airflow Obstruction Following a Beta-Agonist 5 Flow (l/s) Volume (l) Pre-albuterol Post-albuterol Predicted
8 Obstructive Diseases Asthma reversible airflow obstruction, different phenotypes, inflammation prominent Emphysema (COPD) permanent, enlargement/destruction of the respiratory bronchioles Chronic Bronchitis sputum production 3 months/year for 2 years
9 Interrelationship of Diseases Causing Airways Obstruction
10 What is ACOS? A specific definition for ACOS can not be developed until more evidence is available about clinical phenotypes and underlying mechanisms. GINA/GOLD Joint Statement
11 AKA ACOS or COAS ACO Wheezy bronchitis Eosinophilic COPD Neutrophilic Asthma Reversible COPD
12
13
14 Some Proposals for Criteria- ACOS Fixed airway obstruction Previous history of asthma Bronchodilator reversibility Blood eosinophils >5%, Immunoglobulin E >100 IU
15 Patient case A 62-year-old Caucasian woman presents with a chief complaint of cough and shortness of breath that has become progressively more severe over the past two years. She is now having shortness of breath with minimal exercise, occasionally at night, and with respiratory infections.
16 Past medical history: Hypertension on hydrochlorothiazide Hx of asthma while in grade school, but was not treated Had hay fever as a child, but outgrew this Recently had normal dobutamine stress echocardiogram Social history: History professor at local university Currently a nonsmoker, but smoked roughly packs of cigarettes daily through college, graduate school, and the early part of her career with a pack-year history No pets Family history: Father was a long-term smoker and died of lung cancer aged 73 years Mother has exercise-induced asthma and is still living at 87 years
17 Office spirometry FVC: 3.2 L (84% predicted) FEV 1 : 2.0 L (69% predicted) FEV 1 :FVC ratio: 63% predicted FEV 1, forced expiratory volume in 1 s; FVC, forced vital capacity.
18 What are the key points in this patient s history and findings? Older patient (>60 years) Past history of allergies and asthma Smoking history Escalating respiratory symptoms Obstructive lung disease What does she have? Asthma vs COPD
19 Postma DS; Rabe K. N Engl J Med 2015;373:1241-9
20 Hypothetical Course of Lung Function in Chronic Obstructive Pulmonary Disease and Asthma Postma DS; Rabe K. N Engl J Med 2015;373:
21 Differentiating asthma vs COPD Asthma COPD Symptoms before age 40 Common Rare Smoking status Possible ~90% are ex-smokers Nighttime awakenings Common Rare Chronic productive cough Uncommon Common Breathlessness Variable Persistent Atopy Common Possible Day-to-day variability in symptoms Common Uncommon (except during exacerbations) Response to bronchodilator More Less
22 Spirometric measures in asthma, COPD, and ACOS Spirometric variable Asthma COPD ACOS Normal FEV 1 /FVC + Post-BD FEV 1 /FVC < FEV 1 80% predicted FEV 1 <80% predicted Post-BD increase in FEV 1 12% and 200 ml from baseline (reversible airflow limitation) Post-BD increase in FEV 1 12% and 400 ml from baseline (marked reversibility) + +/ BD, bronchodilator; FEV 1, forced expiratory volume in 1 s; FVC, forced vital capacity. Global Initiative for Asthma. Global strategy for Asthma Management and Prevention. Updated
23 Four Examples of Patients with Obstructive Airway Disease Postma DS; Rabe K. N Engl J Med 2015;373:
24 The Overlap Syndrome As many as 50% of older adults with obstructive airway disease have overlapping diagnoses of asthma and COPD This percentage increases linearly with age These patients are often excluded from clinical studies for asthma (because of smoking history) and for COPD (because of at least a partial reversibility of airflow obstruction) Leads to questions for recommended treatment regimens of individual patients with symptom overlap Gibson PG and Simpson JL. Thorax 2009;64:
25 The effect of age on the presence of The Overlap Syndrome Gibson PG and Simpson JL. Thorax 2009;64:
26 Defining Asthma COPD Overlap Syndrome (ACOS) Asthma COPD overlap syndrome is characterized by: Persistent airflow limitation Several features usually associated with asthma Several features usually associated with COPD ACOS is identified by the features it shares with both asthma and COPD, and treatment is directed towards the dominant underlying airway disease
27 Chronic obstructive pulmonary diseases Newer View Asthma COPD A B C D Phenotypes Phenotypes
28 CLUSTER ANALYSIS: 5 CLUSTERS Cluster 1 n=110 Cluster 2 n=321 Cluster 3 n=59 Cluster 4 n=120 Cluster 5 n=116 P-value Age at Enrollment < Gender (%female) Race (% Cauc/AAOther) 62/29/9 63/30/7 73/22/5 62/33/5 68/20/ Body Mass Index (BMI) < Age of Asthma Onset (yrs) < Asthma Duration (yrs) < Baseline Lung Function* FEV1 % Predicted < FVC % Predicted < FEV1/FVC < Maximal Lung Function FEV1 % Predicted < FVC % Predicted < Atopy: % with 1 pos 85% 78% 64% 83% 66% skin test *Pre-bronchodilator values (>6 hours withhold of bronchodilators). Post-bronchodilator values after 6-8 puffs of albuterol Moore et al. AJRCCM 2010; 181:
29 CLUSTER ANALYSIS: 5 CLUSTERS Cluster 1 n=110 Cluster 2 n=321 Cluster 3 n=59 Cluster 4 n=120 Cluster 5 n=116 P-value Corticosteroid Use (%) None Low-moderate dose ICS High dose ICS* Oral or Systemic CS** 45% 38% 10% 11% 31% 40% 28% 10% 14% 37% 49% 17% 15% 18% 63% 39% 5% 16% 78% 47% < Total Controllers(%) None % 41% 19% 26% 46% 29% 10% 35% 54% 12% 33% 56% 4% 28% 67% < Health Care Utilization Pst Yr None 1 Urgent Visit and/or ED 3 Oral CS burst/yr Hospitalization 67% 20% 11% 7% 61% 25% 19% 9% 41% 34% 36% 15% 38% 39% 46% 23% 32% 42% 42% 28% < * High dose ICS dose equivalent to 1000 fluticasone propionate daily; **Chronic oral corticosteroids (OCS) 20 mg daily or other systemic steroids in the past 3 months. Controllers include LTRA, ICS, LABA, theophyllines, OCS, omalizumab. P value from Chi-Square Analysis of ranked ordinal composite variables. Moore et al. AJRCCM 2010; 181:
30 Smoking and Asthma In asthma, smoking can: Make airway inflammation more neutrophilic (Thomson et al. Clin Exp All 2003, Boulet et al. Chest 2006) Make asthma more difficult to control (Polosa et al. ERJ 2012, Boulet et al. Chest 2006) Reduce symptom perception (Kleis S, et a. Respir Med. 2007) Reduce response to asthma drugs (Livingston et al. Drugs 2005) Accelerate loss of pulmonary function and induce fixed airway obstruction (Lange NEJM 1998)
31 Model of symptom/risk of evaluation of COPD Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated
32 The Eosinophilic Phenotype? Some patients have elevated levels of eosinophils in bloodno features of asthma; a predictive biomarker of ICS responsiveness. FLAME trial1: patients on LABA+LAMA QD had fewer exacerbations and hospitalizations than BID ICS. WISDOM trial 2 :withdrawal of ICS did not increase exacerbations of COPD. But chance of exacerbating off ICS greater when eosinophil count >300 cells/mcl Question: Non-eosinophilic type of COPD no ICS? Eosinophilic Phenotpe of COPD early ICS? 1. Manussen et al NEJM Wedzicha et al NEJM 2016
33 The characteristics of patients with asthma, COPD, and the overlap phenotype AHR, airway hyperresponsiveness. Postma DS et al. Clin Chest Med 2014;35:
34 Hardin M et al. The clinical features of the overlap between COPD and asthma. Respir Res 2011;12:127 Cross-sectional study comparing subjects with COPD and asthma to subjects with COPD alone Hardin M et al. Respir Res 2011;12:127.
35 Characteristics of COPD cases (GOLD stage 2 or greater) with and without physician-diagnosed asthma COPD only COPD and asthma p-value Total subjects Gender male 53.1% 53.1% Age, years Pack-years of smoking < Current smoker 34.2% 38.7% 0.35 BMI kg/m GOLD Stage BODE index Severe exacerbations 17.6% 32.8% Frequent exacerbations 18.0% 42.7% < Hay fever 27.8% 57.0% < FEV 1 % predicted FVC % predicted FEV 1 /FVC BMI, body mass index; FEV 1, forced expiratory volume in 1 s; FVC, forced vital capacity. Hardin M et al. Respir Res 2011;12:127.
36 Subjects (%) Exacerbations: Percentage of frequent and severe exacerbations among subjects with COPD compared with subjects with COPD and asthma Frequent exacerbations Severe exacerbations %* %* % % COPD COPD & asthma **p< for the difference between COPD and COPD with asthma. 0 COPD COPD & asthma Hardin M et al. Respir Res 2011;12:127.
37 Health Care Utilization Numerous studies suggest ACOS associated with lower health-related quality of life Increased exacerbations, hospitalizations More rapid decline of lung function Greater health burden relative to asthma or COPD alone
38 Approaches to Diagnosis of Overlap Syndrome 1. Does the patient have chronic airways disease? 2. If so, is it asthma, COPD, or the overlap syndrome in adults Predominantly asthma Predominantly COPD Global Initiative for Asthma. Global strategy Asthma Management and Prevention. Revised Aug
39 Asthma vs. COPD Clinical Differentiation Between Asthma and COPD Asthma COPD Symptoms Before Age 40 Common Rare Smoking Status Possible ~90% are ex-smokers Nighttime Awakenings Common Rare Chronic Productive Cough Uncommon Common Breathlessness Variable Persistent Atopy Common Possible Day to Day Variability in Symptoms Common Response to Bronchodilator More Less Uncommon (Except during exacerbations)
40 Approaches to Diagnosis of Overlap Syndrome 1. Does the patient have chronic airways disease? 2. If so, is it asthma, COPD, or the overlap syndrome in adults Predominantly asthma Predominantly COPD 3. Spirometry Essential Global Initiative for Asthma. Global strategy Asthma Management and Prevention. Revised Aug
41 Characteristics of the Overlap Syndrome Gibson PG and Simpson JL. Thorax 2009;64:
42 Approaches to Diagnosis of Overlap Syndrome 1. Does the patient have chronic airways disease? 2. If so, is it asthma, COPD, or the overlap syndrome in adults Predominantly asthma Predominantly COPD 3. Spirometry Essential 4. Specialized evaluations Global Initiative for Asthma. Global strategy Asthma Management and Prevention. Revised Aug
43 Specialized investigations to distinguish asthma and COPD Asthma COPD Lung function tests DLCO Normal (so slightly elevated) Often reduced Arterial blood gases Normal between exacerbations May be chronically abnormal between exacerbations in more severe forms of COPD Airway hyperresponsiveness (AHR) Not useful on its own in distinguishing asthma form COPD, but high levels of AHR favor asthma Imaging High resolution CT Cscn Inflammatory biomarkers Test for atopy (specific IgE and/or skin prick tests) FeNO Usually normal but air trapping and increased bronchial wall thickness may be observed Modestly increases probability of asthma; not essential for diagnosis A high level (>50 ppb) in non-smokers supports a diagnosis of eosinophilic airway inflammation Low attenuation areas denoting either air trapping or emphysematous change can be quantitated; bronchial wall thickening and features of pulmonary hypertension may be seen Conforms to background prevalence; does not rule out COPD Usually normal. Low in current smokers Blood eosinophilia Supports asthma diagnosis May be present during exacerbations Sputum inflammatory cell analysis Not established in large populations Global Initiative for Asthma. Global strategy Asthma Management and Prevention. Revised Aug
44 CT scanning CT scan pre and post bronchodilators in ACOS patients vs COPD lower extent of emphysema and different distribution (Upper predominance) Greater post BD variation in air trapping Suggesting ACOS is a different phenotype from COPD. Gao, J et al. International J of COPD :
45 Approaches to Diagnosis of Overlap Syndrome 1. Does the patient have chronic airways disease? 2. If so, is it asthma, COPD, or the overlap syndrome in adults Predominantly asthma Predominantly COPD 3. Spirometry Essential 4. Specialized evaluations 5. Initiate treatment Predominantly asthma combination therapy Predominantly COPD (bronchodilators or combination therapy not ICS alone) Global Initiative for Asthma. Global strategy Asthma Management and Prevention. Revised
46 Patient case A 62-year-old Caucasian woman presents with a chief complaint of cough and shortness of breath that has become progressively more severe over the past two years. She is now having shortness of breath with minimal exercise, occasionally at night, and with respiratory infections.
47 Treatment approaches to ACOS Asthma COPD COPD Anti-inflammatory Rx Asthma Bronchodilators (LABAs, LAMAs)
48 In Summary A specific definition for ACOS can not be developed until more evidence is available about clinical phenotypes and underlying mechanisms. GINA/GOLD Joint Statement
49 The REAL reason dinosaurs became extinct...
50 References Postma, DS and Rabe KF. The Asthma-COPD Overlap Syndrome. NEJM : Bonten TN et al Defining asthma-copd overlap syndrome: a population-based study. Eur Respir J : Jo, Yong Suk et al. Different prevalence and clinical characteristic of asthma-chronic obstructive pulmonary disease overlap syndrome according to accepted criteria. Ann Allergy Asthma Immunol : Rodrigue, C. et al. Characterization of Asthma-Chronic Obstructive pulmonary disease overlap syndrome: A qualitative analysis. J of COPD : Cosio BG. Et al. Th-2 signature in chronic airway diseases: towards the extinction of asthma- COPD overlap syndrome? Eur Respir J : Timmola M, et al. Differences between asthma-copd overlap syndrome and adult-onset asthma. Eur Respir J : Hines, KL and Peebles, RS. Management of the Asthma-COPD Overlap Syndrome (ACOS): a review of the evidence. Curr Allergy Asthma Rep :15 Fragoso, C et al. Asthma-COPD overlap syndrome in the US: a prospective population-based analysis of patient-reported outcomes and health care utilization. International J of COPD : Gao, J et al. Characterization of sputum biomarkers for asthma-copd overlap syndrome. International J of COPD : Cazzola M and Rogliani P. Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? JACI :
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More informationTHE COPD-ASTHMA OVERLAP SYNDROME
THE COPD-ASTHMA OVERLAP SYNDROME NICOLA A. HANANIA, MD, MS, FRCP(C), FCCP, FACP ASSOCIATE PROFESSOR OF MEDICINE DIRECTOR OF ASTHMA & COPD CLINICAL RESEARCH CENTER BAYLOR COLLEGE OF MEDICINE HOUSTON, TX
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationAsthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationHow to distinguish between uncontrolled and severe asthma
How to distinguish between uncontrolled and severe asthma Watch patient using their inhaler. Discuss adherence and barriers to use Compare inhaler technique with a devicespecific checklist, and correct
More informationUpdate on heterogeneity of COPD, evaluation of COPD severity and exacerbation
Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationCurrent Asthma Therapy: Little Need to Phenotype. Phenotypes of Severe Asthma. Cellular Phenotypes 12/7/2012
Subbasement Membrane Thickness(µm) 12/7/212 Current Asthma Therapy: Little Need to Phenotype Phenotypes of Severe Asthma Most mild and to some degree moderate asthmatics respond well to currently available
More informationAsthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management
Asthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management Eugene R. Bleecker, MD Professor and Director, Center for Genomics & Personalized Medicine Research Professor, Translational
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More information7/7/2015. Somboon Chansakulporn, MD. History of variable respiratory symptoms. 1. Documented excessive variability in PFT ( 1 test)
Definition of Asthma GINA 2010: Chronic inflammatory disorder of the airways Airway hyper-responsiveness Recurrent wheezing, breathlessness, chest tightness, coughing Variable, reversible airflow obstruction
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationPhenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc
Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationClinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene
Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Emily S. Wan, John E. Hokanson, James R. Murphy, Elizabeth A. Regan, Barry J. Make, David A. Lynch, James D. Crapo, Edwin K.
More informationYuriy Feschenko, Liudmyla Iashyna, Ksenia Nazarenko and Svitlana Opimakh
2018; 7(1): 74-78 ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating: 5.03 TPI 2018; 7(1): 74-78 2018 TPI www.thepharmajournal.com Received: 11-11-2017 Accepted: 12-12-2017 Yuriy Feschenko Liudmyla Iashyna
More informationCOPD and Asthma: Similarities and differences Prof. Peter Barnes
and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton
More informationThe role of lung function testing in the assessment of and treatment of: AIRWAYS DISEASE
The role of lung function testing in the assessment of and treatment of: AIRWAYS DISEASE RHYS JEFFERIES ARTP education Learning Objectives Examine the clinical features of airways disease to distinguish
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationReferring for specialist respiratory input. Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL
Referring for specialist respiratory input Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL Respiratory Specialist- who? GPSI Community Team Secondary Care Respiratory physician and
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationBiologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation
More informationCOPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases
COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases «If you test one smoker with cough every day You will diagnose
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationDisclosures. Update on COPD & Asthma. Update on the Management of COPD. No Pharma Disclosures. NHLBI - Asthma Clinical Research Network
Update on COPD & Asthma Michael C. Peters, M.D. MAS Division of Pulmonary & Critical Care Medicine Cardiovascular Research Institute University of California San Francisco UCSF Primary Care Medicine San
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2017?
Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome
More informationSupplementary Online Content
Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationUsing Patient Characteristics to Individualize and Improve Asthma Care
Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine
More informationIdentification of Asthma Phenotypes using Cluster Analysis in the Severe Asthma Research Program
Moore online supp 1 Online Data Supplement Identification of Asthma Phenotypes using Cluster Analysis in the Severe Asthma Research Program Wendy C. Moore, MD, Deborah A. Meyers, PhD, Sally E. Wenzel,
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationAsthma-chronic obstructive pulmonary disease overlap syndrome in Poland. Findings of an epidemiological study
Original paper Asthma-chronic obstructive pulmonary disease overlap syndrome in Poland. Findings of an epidemiological study Dorota Brzostek, Marek Kokot Takeda Poland Postep Derm Alergol 2014; XXXI, 6:
More informationSGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life
SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More information#POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA
Where There s Smoke There s Obstruction Stephen G. Basheda, D.O., F.C.C.P. 1 Disclosures Dr. Basheda is an independent contractor for AstraZeneca Pharmaceuticals, LP and GlaxoSmithKline and on the speaker
More informationASTHMA. Dr Liz Gamble BRI
ASTHMA Dr Liz Gamble BRI Diagnosis Clinical: wheeze, breathlessness, chest tightness, cough Variable airflow obstruction: peak flow chart, spirometry with reversibility to bronchodilators Airways hyper-responsiveness
More informationAsthma ASTHMA. Current Strategies for Asthma and COPD
Current Strategies for Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor of Medicine Chair, Department of Medicine University of California San Francisco (UCSF) San Francisco,
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationAsthma Pathophysiology and Treatment. John R. Holcomb, M.D.
Asthma Pathophysiology and Treatment John R. Holcomb, M.D. Objectives Definition of Asthma Epidemiology and risk factors of Asthma Pathophysiology of Asthma Diagnostics test of Asthma Management of Asthma
More informationSevere Asthma(s): Can THEY be prevented or reversed?
Severe Asthma(s): Can THEY be prevented or reversed? Sally Wenzel, MD Professor of Medicine UPMC Chair in Translational Airway Biology Disclosures Sally Wenzel, M.D. Grant/Research Support: Boehringer-Ingelheim,
More informationWhat do pulmonary function tests tell you?
Pulmonary Function Testing Michael Wert, MD Assistant Professor Clinical Department of Internal Medicine Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical
More informationALL THAT WHEEZES IS NOT ASTHMA: MIMICS OF ASTHMA
ALL THAT WHEEZES IS NOT ASTHMA: MIMICS OF ASTHMA Tim Op t Holt, EdD, RRT, AE- C, FAARC Professor Cardiorespiratory Care University of South Alabama Mobile I have no conflict of interest related to this
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 31 Oct 2018 11:13:48 GMT) CTRI Number Last Modified On 17/01/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationAmanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ
Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationThe Clinical Phenotype of Asthma in Obesity. Anne Dixon, MA, BM, BCh
The Clinical Phenotype of Asthma in Obesity Anne Dixon, MA, BM, BCh Outline Epidemiology How obesity effects clinical phenotype Phenotypes of asthma in the obese Obesity Trends* Among U.S. Adults BRFSS,
More information9/22/2015 CONFLICT OF INTEREST OBJECTIVES. Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR
Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST
More informationUnderstanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR
Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST
More informationAsthma Therapy 2017 JOSHUA S. JACOBS, M.D.
Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. BACKGROUND-PREVALENCE Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence is increasing
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationCommunity COPD Service Protocol
Community COPD Service Protocol Acknowledgements This protocol is based on the following documents: 1. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationAsthma 2015: Establishing and Maintaining Control
Asthma 2015: Establishing and Maintaining Control Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, APRN, NP-C, AE-C June 16, 2015 Asthma Prevalence Approx. 26
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationPrimary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD
Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationPulmonary Year in Review
Pulmonary Year in Review Rachel Givelber, MD University of Pittsburgh SOM Pulmonary, Allergy, Critical Care and Sleep Medicine Rachel Givelber, MD Assistant Professor of Medicine PACCM, UPSOM Disclosures
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationCOPD: From Phenotypes to Endotypes. MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI
COPD: From Phenotypes to Endotypes MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI Presenter Disclosures MeiLan K. Han Consulting Research support Novartis
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationHeterogeneity of COPD and Asthma
Heterogeneity of COPD and Asthma from Heterogeneity to Stratification Dr. Y-M Oh Asan Medical Center Seoul Congratulations & Welcome Lee,SD Ohno, Y Park, JS Seo, JB 8 th Internat nal Workshop on Pul. Functional
More informationUpdate in Pulmonology Update in Medicine and Primary Care November 11, 2017
Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Denitza P. Blagev, MD Pulmonary & Critical Care Medicine Director, Schmidt Chest Clinic Director, Lung Cancer Screening Program
More informationCurrent Approaches to Asthma & COPD
10/11/18 Current Approaches to Asthma & COPD Lekshmi Santhosh, M.D. Assistant Professor, Pulm/Critical Care & Hosp Med Primary Care Medicine: Principles & Practice 10.11.2018 Revisiting the Dutch Hypothesis:
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationCOPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer
COPD/ Asthma Dr Heather Lewis Honorary Clinical Lecturer Objectives To understand the pathogenesis of asthma/ COPD To recognise the clinical features of asthma/ COPD To know how to diagnose asthma/ COPD
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationAsthma and COPD. Health Net Provider Educational Webinar
Asthma and COPD Health Net Provider Educational Webinar AstraZeneca 2015 Disclosures Presenters today are employed by Astra Zeneca and have nothing to disclose. This presentation is free from bias. 2 Objectives
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationPhenotype of asthma-chronic obstructive pulmonary disease overlap syndrome
review Korean J Intern Med 2015;30:443-449 of asthma-chronic obstructive pulmonary disease overlap syndrome Chin Kook Rhee Division of Pulmonary Critical Care Medicine, Department of Internal Medicine,
More informationAsthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
More informationDifficult Asthma Assessment: A systematic approach
Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationRobert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network
Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert.kruklitis@lvh.com Correlation of a Asthma pathophyisology with basic science Asthma (Physiology) Bronchodilators
More information